KalVista Pharmaceuticals, Inc. 4/A SEC Filings

Filed On	Filing
22 May 2023	Form 4/A: Yea Christopher, Chief Development Officer Exercised 2,430 Restricted Stock Unit
22 May 2023	Form 4/A: Palleiko Benjamin L, President, CFO, CBO & Sec'y Exercised 6,944 Restricted Stock Unit
22 May 2023	Form 4/A: Feener Edward P., Chief Scientific Officer Exercised 2,430 Restricted Stock Unit
22 May 2023	Form 4/A: Crockett Thomas Andrew, Director Exercised 6,944 Restricted Stock Unit
22 May 2023	Form 4/A: Audhya Paul K., Chief Medical Officer Exercised 4,027 Restricted Stock Unit
07 May 2021	Form 4/A: Feener Edward P., Chief Scientific Officer Sold 6,000 shares ($149K)
24 Jan 2019	Form 4/A: Yea Christopher, Chief Development Officer Granted 116,810 Employee Stock Option (Right to Buy)
18 Sep 2017	Form 4/A: Novo Holdings A/S, 10% owner Sold 25,900 shares ($208K) · Sold 10,000 shares ($80.5K) · Sold 140,744 shares ($986K)
27 Apr 2015	Form 4/A: Cha Albert, Director Received 3,192,062 shares by conversion · Bought 1,012,500 shares ($5.06M)
24 Apr 2015	Form 4/A: Vivo Ventures VI, Llc, 10% owner and 2 others Received 3,192,062 shares by conversion · Bought 1,012,500 shares ($5.06M)

Comments